ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALGS vs MGX // EV/EBITDA & P/E VALUATION

Aligos Therapeutics Inc. (NASDAQ) VS. Metagenomi Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALGS 4 — MGX 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALGS VS. MGX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALGS MGX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -39.50% -51.80% +12.30 ALGS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 ALGS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.1 30.9 +10.15 ALGS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $31.4M $31.4M $47.6K ALGS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALGS REV MGX REV ALGS GROSS % MGX GROSS % ALGS FCF MGX FCF
FY 2025 $2.2M $25.2M — — -$82.5M -$89.5M
FY 2024 $3.6M $52.3M — — -$80.9M -$112.2M
FY 2023 $6.2M $44.8M — — -$79.0M -$91.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALGS // BETA —
MGX // BETA —